Tolemy Bio lands €1.4M to power AI-driven cell biology

2026-05-12 · Source: Tech.eu - Tech.eu · Field: Science & Research — Artificial Intelligence & Machine Learning, Life Sciences & Biology, Pharmaceuticals & Biotechnology · Depth: Fundamental Awareness, quick

Summary

Tolemy Bio, a Cambridge-based biotech startup, has secured €1.4 million in pre-seed funding to advance its AI-enabled cell biology platform, Orbit. The funding round was led by Norrsken Evolve, with additional participation from Big Sur Ventures, JME Ventures, Masia, and a new UK-based stealth fund. Orbit aims to address the challenge of manual and fragmented experimental workflows in biopharma and cell biology, where research data is often scattered across various systems. The platform integrates existing lab tools and experimental data with virtual cell models and AI research agents to help scientists analyze cellular behavior and optimize drug development. The new capital will expand Tolemy Bio's data generation, machine learning, and engineering capabilities, further develop Orbit, and support early customer and partner deployments.

Key takeaway

For investors evaluating early-stage biotech, Tolemy Bio's successful pre-seed round highlights growing interest in AI-driven solutions for cell biology. You should consider the market's appetite for platforms that consolidate fragmented research data and apply AI to accelerate drug development, as this represents a significant opportunity to move beyond traditional trial-and-error methods in biopharma.

Key insights

Tolemy Bio's Orbit platform unifies fragmented cell biology data with AI to streamline biopharma research.

Principles

• AI can optimize complex cell biology experiments.
• Fragmented data hinders AI application in biopharma.

Method

Orbit connects existing lab tools and experimental data sources, integrating virtual cell models and AI research agents to analyze cellular behavior and guide experimental decisions.

In practice

• Integrate lab data into a single AI-native environment.
• Utilize virtual cell models for predictive analysis.

Topics

• Tolemy Bio
• Orbit Platform
• AI-enabled Cell Biology
• Biopharma Development
• Pre-seed Funding

Best for: Investor, Research Scientist, AI Scientist, Director of AI/ML

Related on AIssential

• ChemT Biotechnology Raises US$5 Million in 18 months to bring AI to Biomanufacturing — AI-driven virtual cell platforms can precisely guide cell behavior to enhance biomanufacturing efficiency and scalability.
• Tevogen Bio’s Journey to Streamlining Life-Saving Therapies — Integrating a data lakehouse architecture with ML significantly accelerates drug discovery target identification.
• Graph Therapeutics brings total funding to over $10M to advance precision immunology — AI-powered analysis of live patient cells, multi-omics data, and functional biology decodes immune dysfunction for precision immunology.
• Introducing Perceptic: the AI operating system for drug development — AI can accelerate drug development by connecting multi-modal evidence and decisions across the entire drug lifecycle.
• He Raised $70M to Cure Every Disease With AI — AI agents, particularly specialized models, significantly accelerate scientific discovery by removing human talent bottlenecks and enabling high-throughput reasoning.
• The Dog That Hacked Cancer — AI tools can accelerate personalized medicine development, even for non-experts.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Tech.eu - Tech.eu.